Here's what drove the quarter.
Bristol-Myers Squibb said that non-GAAP earnings came in at $1.22 a share, which was well ahead of analysts' expectations of 94 cents and up 30% from the same period last year.
And then the company forecasts non-GAAP earnings of $6 to $6.20 a share, with revenue rising to between $40.5 and $42.5 billion in the financial year of 2020.
Sales of Opdivo, which is Bristol-Myers blockbuster Immuno-oncology drug, fell 2% to $1.76 billion, which came in shy of the FactSet consensus of $1.79 billion.
And Bristol-Myers noted that it “progressed our strategy through the acquisition of Celgene.”
Watch the video above for more.
Online real estate platform CrowdStreet delivers investors a new way to diversify their portfolios with real estate. Individual investors can use CrowdStreet’s leading online marketplace to connect with a wide array of commercial real estate opportunities and projects to make investing in real estate easy! Download the Real Estate Guide.